Here are four things to know about the ongoing shortage.
1. Atenolol is commonly prescribed to patients with high blood pressure because it is inexpensive, only needs to be taken once a day and has fewer side effects than other beta blockers like metoprolol tartrate, metoprolol succinate and bisoprolol.
- Four generic drugmakers — Mylan Pharmaceuticals, Teva Pharmaceuticals, Zydus Pharmaceuticals and Sandoz — reported decreased inventory levels of atenolol to the FDA’s drug shortage database July 26.
- Mylan, Sandoz and Teva cited the lack of an active ingredient as the main reason for the shortages, while Zydus cited increased demand.
- Zydus increased manufacturing capacity and said atenolol was readily available for distribution as of Oct. 19. Teva has a limited atenolol inventory and will allocate the drug as necessary through the fourth quarter of 2017. Mylan, who also has a limited supply of the drug, expects to achieve normal inventory levels in February 2018. Sandoz has not said when it will be able to resupply the drug.
More articles on supply chain:
FDA: Biotin supplements may interfere with lab tests
Gilead launches hepatitis drug in China at one-fifth the US price
Study: Hospitals markup drugs 487%, receive 2.5 times what they paid after negotiations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
